Monjuvi + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination for 2L+ Follicular Lymphoma Patients (MAT-MON-00929)

Event Date:

Apr 23, 2026

Credit Type:

--

Credits:

--